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Abstract: Long-term experience in the treatment of HIV-infected individuals has 
shown indirect benefits of early initiation on antiretroviral therapy, particularly in 
preventing HIV transmission. With the advent of direct-acting antivirals for the 
treatment of hepatitis C, the preventive strategy of treatment-as-prevention has 
become feasible. However, economic, clinical, ethical and public health issues arise 
from the concept of using therapeutic interventions only as prevention strategies.  
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1. Introduction 
After decades of use of highly-active antiretroviral therapy (HAART), long-term 
benefits besides suppressing HIV replication have been found. Early initiation of 
HAART has been associated with decreased mortality1, increasing life expectancy 
both in low and high-income countries2,3, as well as with a significant reduction in the 
incidence of opportunistic infections4. But arguably, one of the most encouraging 
indirect benefits of early initiation of HAART is the reduction of HIV transmission 
among serodiscordant couples5. The use of HAART in the context of treatment-as-
prevention (TasP) might thus represent the most important paradigm change in HIV 
prevention for decades. 
Hepatitis C (HCV) infection is experiencing a similar revolution with the development 
of direct-acting antivirals (DAA), resulting in highly efficacious regimens with very 
favourable safety profiles6. Furthermore, and unlike with interferon (IFN) based 
therapies, the efficacy and safety of DAA in HIV/HCV-coinfected patients is not 
significantly different from that observed in HCV-monoinfected patients7. Hence, 
although their natural histories are different, HIV and HCV share common transmission 
routes, and safe and efficacious therapies are available for both conditions, making 
TasP a potentially feasible strategy for decreasing the incidence of HCV infection, 
especially in high-risk populations (Table 1). 
 
2. Treatment as prevention for HIV infection 
Since the advent of HAART in the mid 90s, the worldwide prevalence of HIV has 
escalated as a consequence of the increase in the number of patients on antiretroviral 
therapy8 and the subsequent reduction of opportunistic infections and other AIDS-
related deaths4. However, the incidence of HIV infection has not significantly changed 
in recent years, due to the increase in new HIV diagnoses in areas such as Eastern 
Europe, Middle East and Central Asia8. HIV prevention remains a major challenge, 
particularly since a significant proportion of HIV patients are unaware of their status9.  
An interim analysis of the HPTN-052 trial10 showed that starting HAART in the HIV-
infected partner in a serodiscordant couple reduced the risk of linked transmission by 
96%. After a 5-year follow-up of the same cohort5 the risk reduction was 93%, thus 
confirming the efficacy of TasP in serodiscordant couples in the long term. Similar 
results were found in trials in South Africa11 and China12. 
In light of the available evidence, and regardless of other strategies for preventing HIV 
transmission such as pre-exposure prophylaxis (PrEP), TasP has shown a remarkable 
efficacy in reducing linked transmission of HIV. 
 
3.  DAA for the prevention of HCV transmission in PWID 
The development of DAA for the treatment of HCV infection can be considered as the 
most significant milestone in the history of HCV since its discovery in 1989. Previous 
IFN-based therapies required lengthy treatments, with a high rate of adverse events, 
often leading to therapy discontinuation or persisting for long periods after therapy 
completion. The efficacy of such therapies was highly variable depending on HCV 
genotype13, with particularly poor results for HIV/HCV-coinfected individuals14. 
Besides, IFN-based therapies were contraindicated in patients with decompensated 
cirrhosis. Altogether, these features restricted patient eligibility for antiviral therapy and 
made the concept of TasP for HCV infection unthinkable.  
The development of DAA dramatically changed the landscape of HCV therapy, 
particularly in light of the efficacy and safety of all-oral treatments15-17. TasP thus 
became feasible, in a similar way to HIV infection. 
Due to the different routes of transmission, TasP faces different challenges depending 
on the risk group involved. In many countries, injection drug use (IDU) accounts for 
the majority of new cases of HCV infection18. Hence, people who inject drugs (PWID) 
are arguably the population who theoretically might benefit the most from TasP. 
Several mathematical models and studies have assessed the effects of this strategy 
in active IDU. An early mathematical model19 showed that the efficacy and efficiency 
of TasP was highly dependent on HCV prevalence among PWID. In low prevalence 
scenarios, a modest increase in the number of PWID treated might have a moderate 
impact on the reduction of HCV incidence. However, in areas with higher HCV 
prevalence among PWID, a much higher number of PWID would need to be treated 
in order to achieve a significant decrease in HCV incidence. Of note, this mathematical 
model did not assess the impact of risk compensation, which has been found to play 
a major role in the efficacy of other prevention strategies in HIV20,21, as confirmed by 
recent studies in patients receiving PrEP22. Another important aspect this 
mathematical model does not consider is the rate of reinfection, which might 
significantly decrease the efficacy of TasP among HCV-infected PWID. 
Another mathematical model23 identified PWID as a target population for TasP in order 
to reduce new cases of HCV infection and prevent liver-related morbidity and mortality. 
Considering several scenarios differing in the degree of intervention, from merely 
pharmacological, to escalation on to linkage to care, diagnosis and enhancing 
adherence, this study found that pharmacological interventions alone achieved very 
modest results. Interestingly, the model that provides the best results implied a 
significant escalation in behavioural interventions. The authors identified some 
caveats when interpreting the results. Firstly, the effect of risk compensation and/or 
reinfection was not completely assessed, making results valid only assuming certain 
rates of reinfection or persisting risk behaviours. On the other hand, ?medication costs 
would make the optimal model difficult to implement and sustain with the current costs 
of drugs and the increased need for medical and other support measures. 
In light of the scarce evidence available to date, wholly based on mathematical 
models, and while waiting for real-world data, DAA could be potentially used for 
prevention. However, mathematical models concur in the significant impact of 
persisting risk behaviours and subsequent reinfections, as well as cost and ethical 
implications. 
 
4. Treatment as prevention of sexually-transmitted HCV 
In recent years, outbreaks of sexually-transmitted HCV have been reported, 
particularly among men who have sex with men (MSM)24. Traditionally HCV has been 
considered a blood-borne virus (BBV), leaving other risk groups aside from regular 
screening for HCV. That has resulted in a significant increase in the incidence of 
sexually-transmitted HCV, particularly among MSM25. This public health issue is even 
more concerning among HIV infected MSM, in whom a 20-fold increase in incidence 
has been reported over the last two decades26. Though sexual transmission is 
significantly less efficient than parenteral transmission, some studies have reported 
seroconversion rates of up to 1.9 cases/100 person-years26. Behavioural factors such 
as inconsistent condom use27, non-injectable illicit drug use28 or traumatic sexual 
intercourse29 have been associated with higher HCV seroconversion rates.  
Data about TasP in MSM is still scarce. A mathematical model based on HCV 
transmission among the UK HIV-positive MSM population30 showed that significant 
reductions in HCV prevalence might be obtained by a scale-up of 80% in DAA 
treatment in HIV/HCV-positive individuals within the first year of diagnosis, regardless 
of the degree of liver fibrosis. However, behavioural interventions might enhance the 
efficacy of TasP, further reducing transmission risk by an additional 20%. This model 
also revealed the significant impact of reinfection on the efficacy of TasP as well as on 
the sustainability of the proposed interventions. Another study31, revealed that 
stabilising high-risk behaviour in conjunction with enhancing access to DAA can 
significantly reduce HCV transmission among HIV-infected MSM individuals. Of note, 
this study was consistent with other models in finding risk compensation as a key factor 
for the success of TasP for HCV prevention. In this line, some authors32 also suggest 
that an increase in reinfection rates can be expected as a consequence of the 
increased uptake of DAA and their lack of side effects, creating an environment of lack 
of concern about reinfection, similarly to what has been observed in HIV transmission.  
So far, further real-world data is necessary to assess the efficacy of DAA for TasP as 
a prevention strategy for sexually-transmitted HCV. Currently, the few mathematical 
models available are based on HIV-infected populations, and the need for evidence 
on HIV-negative individuals remains unmet. With the evidence available, the efficacy 
of TasP for preventing sexually-transmitted HCV would require a significant increase 
in the number of patients treated, with an associated increase in costs that many 
healthcare systems would not be able to sustain. Besides, behavioural interventions 
might be necessary to maximise the efficacy of TasP and reduce the number of 
reinfections and development of resistance. 
 
5. Risk of reinfection  
Arguably, costs are a major barrier for accessing DAA therapies in many countries, 
either due to being low-income? countries or due to high HCV prevalence33. There is 
no doubt that DAA are superior to the previous IFN-based therapies, even in 
genotypes 2 and 3, in which the response to IFN-based treatments was already very 
good34. However, therapy costs limit the cost- of these new treatments35 and pose an 
ethical dilemma on which populations should be prioritised for treatment. International 
guidelines36, 37 concur in recommending that all HCV-infected patients should be 
treated with oral agents, with the exception of those with short life expectancy due to 
liver disease, in which antiviral therapy is not recommended. Such broad 
recommendations pose a significant challenge for doctors, who ultimately have to 
make the best use of the available resources and maximise the numbers of cured 
patients. 
PWID have been described as an ideal population for TasP38. Higher rates of HCV 
prevalence make, in theory, interventions among this population more likely to be 
effective. However, data shows that treating active injecting individuals regardless of 
their degree of liver disease may be an inefficient intervention. Firstly, studies have 
shown that the leading cause of mortality among PWID who achieve SVR after 
antiviral treatment are related to the persistent use of drugs, rather than liver cancer39. 
Hence, even though scaling up the access of PWID to DAA might potentially reduce 
HCV prevalence among this population, IDU remains the most significant preventable 
cause of morbidity and mortality among PWID, and should be addressed as part of 
the care pathway for this population. 
Another important factor to be considered is the risk of reinfection (Figure 1), which 
has been found to play a major role in the efficacy of TasP both for PWID and MSM. 
Whereas evidence supports the efficacy of DAA therapies in PWID, reinfection 
accounted for the majority of late relapses in some registration clinical trials, 
particularly among patients on opiate replacement therapy40. A study on a mixed 
cohort of HIV/HCV-coinfected and HCV-monoinfected individuals treated for HCV 
infection41 found a reinfection rate of 7.4 cases/100 persons-year. However, in patients 
who reported active injection drug use after therapy, that rate was twice as high 
(15.5/100 persons-year). Active IDU after therapy was also strongly associated with 
reinfection. Of note, the time to reinfection was highly variable among patients. This is 
a significant limitation for TasP, since the period of time in which cured active PWID 
are at reduced risk of transmission is unpredictable. Another study involving a 
population of PWID who had not used drugs 6 months prior to therapy and who had 
achieved SVR after treatment32 found a reinfection rate of 11%, which was as high as 
27% in patients who relapsed IDU after therapy. Finally, some studies have shown 
that reinfection risk among active PWID increases over time after achieving SVR, due 
to a lack of frequent testing and support42. 
Reinfection rates among HCV-positive MSM have been found to be higher than among 
PWID43, with rates of reinfection of up to 24.6% and, most concerning, with a 
significant proportion of patients presenting with second reinfections. Overall, the 
incidence of reinfection among MSM is estimated to be over 7 cases/100 p-y32 (Figure 
2). Though overall, PWID remain as the population with highest HCV prevalence, in 
the near future sexually-transmitted HCV will be of further relevance in public health 
terms. 
 
6. Public health and ethical issues 
Reinfection poses a significant public health risk. Many studies have shown the 
frequent development of resistant-associated variants (RAV) in patients failing 
therapy. This is particularly concerning in patients infected with HCV genotype 3, in 
which the use of NS5a inhibitors remains essential44. The development of RAVs 
against NS5a inhibitors tends to confer cross-resistance with all the currently available 
drugs of this class, and these RAVs might be present even 5 years after their 
emergence45. Hence, a scaling up of DAA therapies for patients at high risk of 
reinfection might be followed by an increase in the prevalence of RAV, which may 
compromise the efficacy of antiviral therapies. This is particularly likely to happen if 
risk compensation increases and behavioural interventions are not implemented in 
order to reduce risk behaviour. Mathematical models concur that risk compensation 
would not just compromise the theoretical efficacy of TasP, but would be also 
jeopardise the efficacy of DAA in general.  
Reinfection after DAA therapy would also cause an ethical dilemma, bearing in mind 
the high prices of these treatments. DAA costs are causing an accessibility issue in 
developing countries46, but also a sustainability issue for public healthcare systems in 
the Western World47. Guidelines remark that all HCV patients are eligible unless their 
life expectancy due to liver disease is poor, and that prioritization should be made on 
the basis of the severity of liver disease36, 37. However, due to economic constraints 
the access to DAA is limited, and might raise the dilemma on whether re-infected 
patients due to risk behaviours should be treated more than once before some other 
patients who are not engaged in such activities are treated for the first time48.  
Arguably, DAA costs are at the core of all the ethical dilemmas arising from TasP in 
active PWID, bearing in mind that in countries with high HCV prevalence, including 
those in the Western world, public healthcare systems are already under economic 
pressure, and maximising the outcomes of interventions is essential for their 
sustainability. Economic implications, public health (RAV development), and ethical 
considerations (equality in the access to DAA) all pose a major dilemma for clinicians.  
 
7. Conclusions 
With the development of DAA, the landscape of HCV therapy has dramatically 
changed, offering new therapeutic strategies. Due to current costs, prioritising the 
access to such therapies to the populations with a higher need of HCV eradication 
remains essential. Besides therapeutic implications, DAA make TasP feasible, unlike 
IFN-based treatments. Unlike HIV, in which ART is currently a life-long treatment, thus 
extending the effects of TasP on the long-term. The high variability in time to 
reinfection in populations engaged in high-risk behaviours makes difficult to assess 
the period of time in which individuals in these populations are not at risk of transmitting 
HCV. 
So far, real-world evidence regarding the efficacy of TasP in HCV infection remains 
scarce, and estimations are based on mathematical models. From the data available, 
two main messages emerge. Firstly, that the economic feasibility of TasP is hardly 
achievable with current costs. And secondly, that pharmacological interventions alone 
are not enough to significantly curb HCV transmission, since risk compensation is a 
limiting factor for its efficacy. Hence, until further real-world evidence is available, TasP 
for HCV transmission has to be looked at carefully and behavioural interventions 
developed in order to maximise the effects of DAA therapies. 
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Figure 1. Reinfection rates in active PWID after achieving SVR 
 
Figure 2. Reinfection rates in MSM after achieving SVR 
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Table 1. Comparison in factors involved in TasP in HIV and HCV 
DAA: direct acting antivirals, HAART: highly active antiretroviral therapy, MSM: men who have sex 
with men, PWID: people who inject drugs, TasP: treatment as prevention 
 
TasP Element HIV HCV 
Target populations Serodiscordant couples 
HIV- positive pregnant 
women 
MSM 
PWID 
MSM 
Intervention HAART DAA 
Intervention duration Lifelong Often 12 weeks (range 8-24) 
Intervention efficacy 80-90% 95-100% 
Intervention adverse effects 
leading to discontinuation 
<5% 0-2%  
Ideal adjunct risk 
modification 
Safe sex promotion and 
condom use 
Services to prevent 
drug/alcohol use 
